Samsung Epis Holdings Launches Its New Investment Holding as Samsung Bioepis
Samsung Epis Holdings Co., Ltd. recently announced its establishment as a new investment holding company, following the spin-off of Samsung Bioepis Co., Ltd. from Samsung Biologics (KRX: 207940.KS). Samsung Epis Holdings will be listed on Korea Exchange (KRX) on November 24, 2025, after the establishment of a new subsidiary company on November 14, 2025. Samsung […]
Samsung Bioepis Partners with NIPRO to Commercialize Biosimilars in Japan
Samsung Bioepis Co., Ltd., on June 8th, announced that the company has entered into a license, development and commercialisation agreement with NIPRO Corporation for multiple biosimilar candidates, including SB17, an ustekinumab biosimilar candidate, in Japan. Under the terms of the agreement, Samsung Bioepis will be responsible for the development, manufacture and supply of the medicines, […]
